Instil Bio, Inc.

NasdaqCM TIL

Instil Bio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2024: USD 120.35 M

Instil Bio, Inc. Cash and Short-Term Investments is USD 120.35 M for the quarter ending September 30, 2024, a -34.39% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Instil Bio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2023 was USD 183.45 M, a -39.51% change year over year.
Instil Bio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2022 was USD 303.29 M, a -41.15% change year over year.
Instil Bio, Inc. Cash and Short-Term Investments for the quarter ending September 30, 2021 was USD 515.36 M.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqCM: TIL

Instil Bio, Inc.

CEO	Mr. Bronson Crouch
IPO Date	March 19, 2021
Location	United States
Headquarters	3963 Maple Avenue
Employees	49
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.

Key trends

Past 5 years